Covered recipient · General Payments record
SMITHA RAJASEKHAR
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$2,765.24
- Reported across 138 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $892.04 | 33 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $332.85 | 16 |
| Gilead Sciences, Inc. | $113.85 | 1 |
| Edwards Lifesciences Corporation | $113.14 | 1 |
| Lilly USA, LLC | $68.57 | 3 |
| Novo Nordisk AS | $63.34 | 3 |
| Exact Sciences Corporation | $49.09 | 2 |
| Merck Sharp & Dohme Corporation | $41.00 | 2 |
| Acerta Pharma LLC | $39.21 | 2 |
| Amgen Inc. | $28.44 | 1 |
| PFIZER INC. | $22.53 | 1 |
| GlaxoSmithKline, LLC. | $20.02 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (33)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $15.62 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105357746 | CMS |
| ABBVIE INC. | $21.40 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105357750 | CMS |
| ABBVIE INC. | $14.07 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105357754 | CMS |
| ABBVIE INC. | $14.43 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105357758 | CMS |
| ABBVIE INC. | $19.22 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105357762 | CMS |
| ABBVIE INC. | $12.10 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105357766 | CMS |
| ABBVIE INC. | $12.63 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105357770 | CMS |
| ABBVIE INC. | $34.77 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105357774 | CMS |
| ABBVIE INC. | $32.43 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105357778 | CMS |
| ABBVIE INC. | $29.90 | 06/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105357782 | CMS |
| ABBVIE INC. | $23.96 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105357786 | CMS |
| ABBVIE INC. | $25.49 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105357790 | CMS |
| ABBVIE INC. | $15.90 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105357793 | CMS |
| ABBVIE INC. | $27.32 | 09/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105357798 | CMS |
| ABBVIE INC. | $21.50 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105357801 | CMS |
| ABBVIE INC. | $12.11 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105357805 | CMS |
| Amgen Inc. | $28.44 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116039082 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.84 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104733425 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.37 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105542223 | CMS |
| Edwards Lifesciences Corporation | $113.14 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138865311 | CMS |
| Exact Sciences Corporation | $20.45 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114845825 | CMS |
| Exact Sciences Corporation | $28.64 | 12/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114845832 | CMS |
| Gilead Sciences, Inc. | $113.85 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133743467 | CMS |
| GlaxoSmithKline, LLC. | $20.02 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115856141 | CMS |
| Lilly USA, LLC | $14.33 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135411879 | CMS |
| Lilly USA, LLC | $24.25 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135380008 | CMS |
| Lilly USA, LLC | $29.99 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135427776 | CMS |
| Merck Sharp & Dohme LLC | $20.87 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141814104 | CMS |
| Merck Sharp & Dohme LLC | $20.13 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141947347 | CMS |
| Novo Nordisk Inc | $23.98 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097482757 | CMS |
| Novo Nordisk Inc | $18.55 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096683132 | CMS |
| Novo Nordisk Inc | $20.81 | 11/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097292297 | CMS |
| PFIZER INC. | $22.53 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130988716 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.